Boston Biomedical: Focused on Innovative Cancer Research

Boston Biomedical is committed to developing innovative next-generation cancer therapeutics. Our most advanced research program involves inhibitors of cancer stem cell (CSC) pathways. In addition, we have several other research approaches targeting cancer stem cell pathways, including peptide vaccines and immune response modifiers, which are in preclinical and early clinical development.

Cancer Stem Cell Research Program

Clinically advanced research efforts at Boston Biomedical involve the use of various proprietary platform technologies to identify and develop therapeutics that target CSC pathways. These technologies allow for the efficient discovery of and research into anti-CSC pathway therapeutics. This is in contrast with conventional drug discovery approaches, which rely on an inefficient, quantity-driven paradigm that employs high-throughput technology in an attempt to manage the biological and chemical complexity required to bring new drugs to market.

The approach used by the Boston Biomedical team has proven to be productive for discovering innovative drug candidates for further study. Currently, Boston Biomedical’s most advanced investigational agents are napabucasin and amcasertib, which are being studied across all phases of clinical development and in multiple tumor types.

Boston Biomedical’s investigational drugs are designed to target CSC pathways. Shown below are results from a preclinical research study: CSCs alone (left), CSCs after receiving a standard chemotherapy (center), and CSCs after receiving one of our investigational drugs targeting a CSC pathway (right). In this preclinical study, standard therapies were not effective against CSCs, but compounds targeting CSC pathways were able to kill CSCs as well as bulk tumor cells.

Preclinical Research

Current Clinical Trials

Our ongoing studies in advanced cancers emphasize inhibition of cancer stem cell pathways.

Learn More

Cancer Stem Cells

Our evolving understanding

  • Stemness
  • Aberrant signaling pathways
  • Resistance to traditional therapies
  • Role in recurrence and metastasis

Learn More